Orally Administered ENT-01 for Parkinson's Disease-Related Constipation Follow-on Safety "Roll-over" Study (Rollover)

Parkinson Disease Clinical Trial

— Rollover  

Official title:

A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04483479
• Other study ID #: ENT-01-2b-20-02
• Status: Terminated
• Phase: Phase 2
• Start date: July 30, 2020
• Est. completion date: February 17, 2022

Study information

• Verified date: February 2024
• Source: Enterin Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will be conducted as an open-label safety follow-on to a multi-center, double-blind, randomized study. All subjects who participated in the randomized study will be offered participation in this unblinded, single-arm, safety study. Approximately 50 subjects will be entered into the study and ENT-01 will be administered daily in escalating doses followed by a fixed dose for 12 weeks. Each subject will participate for approximately 20 weeks; dosing duration will be approximately 14 weeks.

Description:

The study will be conducted on an out-patient or in-patient basis with visits performed at the screening visit, at 6 and 12 weeks, and at the end of the 6th week of the wash-out period (end of study). The dose escalation period will last up to 20 days, the fixed dose period will last 12 weeks, and the wash-out period will last 6 weeks. Subjects will begin dosing at the same dose level they were stratified to in the ENT-01-030 randomized study (i.e., starting at either 3 tablets or 6 tablets,) and escalate up to a pro-kinetic dose or a maximum dose of 250mg.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 27
• Est. completion date: February 17, 2022
• Est. primary completion date: February 17, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years to 90 Years

Eligibility

Inclusion Criteria:

1. All subjects who participated in the randomized study ENT-01-030 (KARMET Stage 2 Extension subjects) and who completed the dosing period.

2. Subjects aged 30-90 years at the time of screening for the ENT-01-030 study, both genders

3. Subjects must provide informed consent and be willing and able to comply with study procedures.

4. Subjects must be able to read, understand, and accurately record data into the diary to guarantee full participation in the study.

5. Female subjects must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. A vasectomized partner will be allowed as one in conjunction with another single-barrier method.

6. Female subjects unable to bear children must have this documented in the CRF (i.e., tubal ligation, hysterectomy, or postmenopausal [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone (FSH) in women less than 60 years of age.

Exclusion Criteria:

1. Unable or unwilling to provide informed consent or to comply with study procedures.

2. Unable to withdraw proton pump inhibitors.

3. Unable or unwilling to withdraw from laxatives, opiates, clonazepam, or any medications which may cause constipation 2 weeks prior to the dose adjustment period and throughout the rest of the study.

4. Diagnosis of secondary constipation beyond that of Parkinson's disease.

5. A compromised gastrointestinal system which includes:

• Structural, metabolic, or functional GI diseases or disorders.
• Acute GI illness within 2 weeks of the screening visit.
• History of major GI surgery within 30 days of the screening visit (a history of cholecystectomy, polypectomy, hernia repair or appendicectomy are not exclusionary as long as they were performed more than 30 days before the screening visit).

6. Neurological disorder other than Parkinson's disease that in the opinion of the investigator might interfere with the conduct of the study.

7. On treatment with intra-jejunal dopamine or carbidopa/levodopa (i.e. Duopa).

8. Subjects starting a new Parkinson's disease medication or modifying an existing medication within 2 weeks prior to enrollment.

9. Unable to maintain a stable diet regimen.

10. Subjects with a cognitive impairment that preclude them from understanding the informed consent.

11. Subjects placed under legal guardianship.

12. History of excessive alcohol use or substance abuse.

13. Any clinically significant abnormalities on screening laboratories or physical examination requiring further evaluation or treatment.

14. Females who are pregnant or breastfeeding.

15. Subject or caregiver unable to administer daily oral dosing of study drug.

16. Participation in a non-Enterin investigational drug trial within the month prior to dosing in the present study.

17. Any other reason, which in the opinion of the investigator would confound proper interpretation of the study.

Related Conditions & MeSH terms

• Constipation
• Parkinson Disease

Intervention

Drug:
• Active Investigational Treatment ENT-01
ENT-01 will be administered in tablet form, once daily in escalating doses followed by a fixed-dose for 12 weeks.

Locations

Country	Name	City	State
United States	Albany Medical College	Albany	New York
United States	JEM Research Institute	Atlantis	Florida
United States	Parkinson's Disease and Movement Disorders Center of Boca Raton	Boca Raton	Florida
United States	Cleveland Clinic	Cleveland	Ohio
United States	Rocky Mountain Movement Disorders Center	Englewood	Colorado
United States	The Parkinson's and Movement Disorder Institute	Fountain Valley	California
United States	Penn State University	Hershey	Pennsylvania
United States	University Physicians & Surgeons, Inc. dba Marshall Health	Huntington	West Virginia
United States	Evergreen Health - Booth Gardner Parkinson's Care Center	Kirkland	Washington
United States	Dartmouth Hitchcock Medical Center	Lebanon	New Hampshire
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	SC3 Research - Pasadena	Pasadena	California
United States	Parkinson's Disease Treatment Center of SWFL	Port Charlotte	Florida
United States	Intercoastal Medical Group	Sarasota	Florida
United States	USF Health Byrd Parkinson's Disease Movement Disorders Center of Excellence	Tampa	Florida
United States	University of Toledo Medical Center	Toledo	Ohio
United States	Georgetown Universtiy, Department of Neurology	Washington	District of Columbia
United States	Premiere Research Institute at Palm Beach Neurology	West Palm Beach	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Enterin Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Treatment Related Adverse Events	Number of participants with Treatment Related Adverse Events	Through study treatment and completion up to 14 weeks
Primary	Number of Participants With Treatment Related Recurrent Vomiting	The number of participants with treatment related episodes of recurrent vomiting defined as 3-5 episodes of vomiting within 24 hours	Through study treatment and completion up to 14 weeks
Primary	Number of Participants With Treatment Related Recurrent Diarrhea	The number of participants with treatment related episodes of recurrent diarrhea defined as 7 episodes of diarrhea within 24 hours for 2 consecutive days	Through study treatment and completion up to 14 weeks
Primary	Number of Participants With Treatment Related Dizziness	The number of participants with treatment related episodes of dizziness defined as lightheadedness or fainting on rising from lying to sitting or standing and severe enough to require non-urgent medical intervention within 24 hours	Through study treatment and completion up to 14 weeks